[1]
Wade, S.W.; Strader, C.; Fitzpatrick, L.A.; Anthony, M.S.; O’Malley, C.D. Estimating prevalence of osteoporosis: Examples from industrialized countries. Arch. Osteoporos., 2014, 9, 182.
[2]
Nelson, H.D.; Haney, E.M.; Chou, R.; Dana, T.; Fu, R.; Bougatsos, C.U.S. Preventive services task force evidence syntheses, formerly
systematic evidence reviews. In: Screening for Osteoporosis: Systematic
Review to Update the 2002 U.S. Preventive Services Task Force Recommendation; Agency for Healthcare Research and
Quality (US): Rockville (MD), 2010.
[3]
Cauley, J.A.; Thompson, D.E.; Ensrud, K.C.; Scott, J.C.; Black, D. Risk of mortality following clinical fractures. Osteoporos. Int., 2000, 11(7), 556-561.
[4]
Center, J.R.; Nguyen, T.V.; Schneider, D.; Sambrook, P.N.; Eisman, J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet, 1999, 353(9156), 878-882.
[5]
Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann. Intern. Med., 2011, 154(5), 356-364.
[6]
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA, 2001, 285(6), 785-795.
[7]
Camacho, P.M.; Petak, S.M.; Binkley, N.; Clarke, B.L.; Harris, S.T.; Hurley, D.L.; Kleerekoper, M.; Lewiecki, E.M.; Miller, P.D.; Narula, H.S.; Pessah-Pollack, R.; Tangpricha, V.; Wimalawansa, S.J.; Watts, N.B. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016--executive summary. Endocr. Pract., 2016, 22(9), 1111-1118.
[8]
Qaseem, A.; Snow, V.; Shekelle, P.; Hopkins, R., Jr; Forciea, M.A.; Owens, D.K. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med., 2008, 148(9), 680-684.
[9]
Cosman, F.; de Beur, S.J.; LeBoff, M.S.; Lewiecki, E.M.; Tanner, B.; Randall, S.; Lindsay, R. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos. Int., 2014, 25(10), 2359-2381.
[10]
Kanis, J.A.; Johnell, O.; Oden, A.; Johansson, H.; McCloskey, E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int., 2008, 19(4), 385-397.
[11]
Tasci, I.; Cintosun, U.; Safer, U.; Naharci, M.I.; Bozoglu, E.; Aydogdu, A.; Doruk, H. Assessment of geriatric predictors of adherence to Zoledronic acid treatment for osteoporosis: A prospective follow-up study. Acta Clin. Belg., 2017, 73(4), 237-243.
[12]
Tasci, I.; Safer, U.; Cintosun, U.; Bozoglu, E.; Naharci, I.; Aydogdu, A.; Meric, C.; Doruk, H. Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis. Endocr. Metab. Immune Disord. Drug Targets, 2016, 16(1), 32-38.
[13]
Watts, N.B.; Lewiecki, E.M.; Miller, P.D.; Baim, S. National Osteoporosis Foundation 2008 Clinician’s Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J. Clin. Densitom., 2008, 11(4), 473-477.
[14]
Schuit, S.C.; van der Klift, M.; Weel, A.E.; de Laet, C.E.; Burger, H.; Seeman, E.; Hofman, A.; Uitterlinden, A.G.; van Leeuwen, J.P.; Pols, H.A. Fracture incidence and association with bone mineral density in elderly men and women: The rotterdam study. Bone, 2004, 34(1), 195-202.
[15]
Solomon, D.H.; Connelly, M.T.; Rosen, C.J.; Dawson-Hughes, B.; Kiel, D.P.; Greenspan, S.L.; Leib, E.S.; Holick, M.; Miguel, A.H.; Finkelstein, J.S. Factors related to the use of bone densitometry: Survey responses of 494 primary care physicians in New England. Osteoporos. Int., 2003, 14(2), 123-129.
[16]
Cheng, N.; Green, M.E. Osteoporosis screening for men: are family physicians following the guidelines? Can. Fam. Physician, 2008, 54(8), 1140-1141.
[17]
Ioannidis, G.; Papaioannou, A.; Thabane, L.; Gafni, A.; Hodsman, A.; Kvern, B.; Walsh, A.; Jiwa, F.; Adachi, J.D. Family physicians’ personal and practice characteristics that are associated with improved utilization of bone mineral density testing and osteoporosis medication prescribing. Popul. Health Manag., 2009, 12(3), 131-138.
[18]
Fogelman, Y.; Goldshtein, I.; Segal, E.; Ish-Shalom, S. Managing Osteoporosis: A Survey of Knowledge, Attitudes and Practices among Primary Care Physicians in Israel. PLoS One, 2016, 11(8)e0160661
[19]
Choi, Y.J.; Oh, H.J.; Kim, D.J.; Lee, Y.; Chung, Y.S. The prevalence of osteoporosis in Korean adults aged 50 years or older and the higher diagnosis rates in women who were beneficiaries of a national screening program: The Korea national health and nutrition examination survey 2008-2009. J. Bone Miner. Res., 2012, 27(9), 1879-1886.
[20]
Weng, W.; Hess, B.J.; Lynn, L.A.; Lipner, R.S. Assessing the Quality of Osteoporosis Care in Practice. J. Gen. Intern. Med., 2015, 30(11), 1681-1687.
[21]
Tuzun, S.; Eskiyurt, N.; Akarirmak, U.; Saridogan, M.; Senocak, M.; Johansson, H.; Kanis, J.A. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporos. Int., 2012, 23(3), 949-955.
[22]
Olomu, A.B.; Corser, W.D.; Stommel, M.; Xie, Y.; Holmes-Rovner, M. Do self-report and medical record comorbidity data predict longitudinal functional capacity and quality of life health outcomes similarly? BMC Health Serv. Res., 2012, 12(1), 398.
[23]
Kriegsman, D.M.; Penninx, B.W.; van Eijk, J.T.; Boeke, A.J.; Deeg, D.J. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients’ self-reports and on determinants of inaccuracy. J. Clin. Epidemiol., 1996, 49(12), 1407-1417.
[24]
Stuart, A.L.; Williams, L.J.; Brennan, S.L.; Kotowicz, M.A.; Pasco, J.A. Poor agreement between self-reported diagnosis and bone mineral density results in the identification of osteoporosis. J. Clin. Densitom., 2015, 18(1), 13-16.
[25]
Chen, Z.; Kooperberg, C.; Pettinger, M.B.; Bassford, T.; Cauley, J.A.; LaCroix, A.Z.; Lewis, C.E.; Kipersztok, S.; Borne, C.; Jackson, R.D. Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women’s Health Initiative observational study and clinical trials. Menopause, 2004, 11(3), 264-274.
[26]
Rothmann, M.J.; Ammentorp, J.; Bech, M.; Gram, J.; Rasmussen, O.W.; Barkmann, R.; Glüer, C.C.; Hermann, A.P. Self-perceived facture risk: factors underlying women’s perception of risk for osteoporotic fractures: The Risk-Stratified Osteoporosis Strategy Evaluation study (ROSE). Osteoporos. Int., 2015, 26(2), 689-697.
[27]
Wenger, N.S.; Solomon, D.H.; Roth, C.P.; MacLean, C.H.; Saliba, D.; Kamberg, C.J.; Rubenstein, L.Z.; Young, R.T.; Sloss, E.M.; Louie, R.; Adams, J.; Chang, J.T.; Venus, P.J.; Schnelle, J.F.; Shekelle, P.G. The quality of medical care provided to vulnerable community-dwelling older patients. Ann. Intern. Med., 2003, 139(9), 740-747.
[28]
Greenspan, S.L.; Perera, S.; Ferchak, M.A.; Nace, D.A.; Resnick, N.M. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern. Med., 2015, 175(6), 913-921.
[29]
Teng, G.G.; Curtis, J.R.; Saag, K.G. Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job? Curr. Osteoporos. Rep., 2009, 7(1), 27-34.
24
2